Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicola J MacLaine

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cell Cycle (Georgetown, Tex.)|February 26, 2011
How phosphorylation controls p53Nicola J MacLaine, Ted R Hupp
Aging|February 17, 2010
The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathwayNicola J Maclaine, Ted R Hupp
Cancer Research|November 9, 2010
Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatinLynnette Marcar, Nicola J Maclaine, Ted R Hupp, et al.
Plos One|August 24, 2012
Exploiting the MDM2-CK1α protein-protein interface to develop novel biologics that induce UBL-kinase-modification and inhibit cell growthAnne-Sophie Huart, Nicola J MacLaine, Vikram Narayan, et al.
The Journal of Biological Chemistry|September 18, 2009
CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stabilityAnne-Sophie Huart, Nicola J MacLaine, David W Meek, et al.
Molecular Cancer Research : MCR|February 1, 2008
Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathwayNicola J MacLaine, Michelle D Wood, Julie C Holder, et al.
European Urology|March 1, 2011
Immortalisation of normal human urothelial cells compromises differentiation capacityNikolaos T Georgopoulos, Lisa A Kirkwood, Claire L Varley, et al.
The Journal of Biological Chemistry|August 2, 2008
A central role for CK1 in catalyzing phosphorylation of the p53 transactivation domain at serine 20 after HHV-6B viral infectionNicola J MacLaine, Bodil Oster, Bettina Bundgaard, et al.
Journal of Immunological Methods|February 25, 2012
Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft modelsTerry A Gray, Nicola J MacLaine, Caroline O Michie, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cell Cycle (Georgetown, Tex.)|February 26, 2011
How phosphorylation controls p53Nicola J MacLaine, Ted R Hupp
Aging|February 17, 2010
The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathwayNicola J Maclaine, Ted R Hupp
Cancer Research|November 9, 2010
Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatinLynnette Marcar, Nicola J Maclaine, Ted R Hupp, et al.
Plos One|August 24, 2012
Exploiting the MDM2-CK1α protein-protein interface to develop novel biologics that induce UBL-kinase-modification and inhibit cell growthAnne-Sophie Huart, Nicola J MacLaine, Vikram Narayan, et al.
The Journal of Biological Chemistry|September 18, 2009
CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stabilityAnne-Sophie Huart, Nicola J MacLaine, David W Meek, et al.
Molecular Cancer Research : MCR|February 1, 2008
Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathwayNicola J MacLaine, Michelle D Wood, Julie C Holder, et al.
European Urology|March 1, 2011
Immortalisation of normal human urothelial cells compromises differentiation capacityNikolaos T Georgopoulos, Lisa A Kirkwood, Claire L Varley, et al.
The Journal of Biological Chemistry|August 2, 2008
A central role for CK1 in catalyzing phosphorylation of the p53 transactivation domain at serine 20 after HHV-6B viral infectionNicola J MacLaine, Bodil Oster, Bettina Bundgaard, et al.
Journal of Immunological Methods|February 25, 2012
Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft modelsTerry A Gray, Nicola J MacLaine, Caroline O Michie, et al.
Pageof 1